Compile Data Set for Download or QSAR
Report error Found 1730 Enz. Inhib. hit(s) with Target = 'Free fatty acid receptor 2'
TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50044849(CHEMBL3311308)
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at human FFA2 receptor expressed in U2OS cells assessed as calcium mobilization after 24 hrs by FLIPRMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFree fatty acid receptor 2(Rat)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50044849(CHEMBL3311308)
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at rat FFA2 receptor expressed in U2OS cells assessed as calcium mobilization after 24 hrs by FLIPRMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFree fatty acid receptor 2(Mouse)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50044849(CHEMBL3311308)
Affinity DataEC50: <3.16E+4nMAssay Description:Agonist activity at mouse FFA2 receptor expressed in U2OS cells assessed as calcium mobilization after 24 hrs by FLIPRMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50044849(CHEMBL3311308)
Affinity DataEC50: <5.01E+4nMAssay Description:Agonist activity against human GPR43 expressed in U2OS cells by BacMam FLIPR/summary (Abse5) assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFree fatty acid receptor 2(Mouse)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50044849(CHEMBL3311308)
Affinity DataEC50: <5.01E+4nMAssay Description:Agonist activity against mouse GPR43 expressed in U2OS cells by BacMam FLIPR/summary (Abse5) assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFree fatty acid receptor 2(Rat)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50044849(CHEMBL3311308)
Affinity DataEC50: <5.01E+4nMAssay Description:Agonist activity against rat GPR43 expressed in U2OS cells by BacMam FLIPR/summary (Abse5) assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50107314(CHEMBL3600993)
Affinity DataEC50: >1.00E+4nMAssay Description:Agonist activity at GPR43 (unknown origin) expressed in CHO cells by FLIPR calcium flux assay in presence of 0.1% bovine serum albuminMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50107305(CHEMBL3601001)
Affinity DataEC50: >1.00E+4nMAssay Description:Agonist activity at GPR43 (unknown origin) expressed in CHO cells by FLIPR calcium flux assay in presence of 0.1% bovine serum albuminMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50107303(CHEMBL3601003)
Affinity DataEC50: >1.00E+4nMAssay Description:Agonist activity at GPR43 (unknown origin) expressed in CHO cells by FLIPR calcium flux assay in presence of 0.1% bovine serum albuminMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403764((2S,5R)-1-(3-((4-chlorobenzyl)oxy)-5-methoxybenzoy...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403767((2S,5R)-5-(2-chlorophenyl)-1-(2'-fluoro-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403773((2S,5R)-5-(2-chlorophenyl)-1-(4'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403786((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-phenetho...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403752((2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-bip...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403787((2S,5R)-1-([1,1'-biphenyl]-4-carbonyl)-5-(2-chloro...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403788((2S,5R)-5-(2-chlorophenyl)-1-(3-(3,3-diphenylpropo...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403789((2S,5R)-5-(2-chlorophenyl)-1-(3'-fluoro-[1,1'-biph...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403790((2S,5R)-5-(2-chlorophenyl)-1-(3'-methyl-[1,1'-biph...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403791((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-((4-(met...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403792((2S,5R)-5-(2-chlorophenyl)-1-(3'-methoxy-[1,1'-bip...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403793((2S,5R)-5-(2-chlorophenyl)-1-(3,5-dimethoxybenzoyl...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403794((2S,5R)-5-(2-chlorophenyl)-1-(4-(phenoxymethyl)ben...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403795((2S,5R)-5-(2-chlorophenyl)-1-(4-((2-fluorobenzyl)o...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403796((2S,5R)-1-(3-chloro-5-methoxybenzoyl)-5-(2-chlorop...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403763((2S,5R)-5-(2-chlorophenyl)-1-(2'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403797((2S,5R)-5-(2-chlorophenyl)-1-(4'-fluoro-[1,1'-biph...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM463345(US10781171, Compound 19)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403799((2S,5R)-5-(2-chlorophenyl)-1-(chroman-3-carbonyl)p...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403800((2S,5R)-5-(2-chlorophenyl)-1-(3,5-diethoxybenzoyl)...)
Affinity DataEC50:  600nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403801((2S,5R)-5-(2-chlorophenyl)-1-(3-phenethoxybenzoyl)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403802((2S)-1-([1,1'-biphenyl]-4-carbonyl)-4-benzyl-5-phe...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403801((2S,5R)-5-(2-chlorophenyl)-1-(3-phenethoxybenzoyl)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403804((2S,5R)-5-(2-chlorophenyl)-1-(2,2-difluorobenzo[d]...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403805((2S,5R)-5-(2-chlorophenyl)-1-(6-phenylnicotinoyl)p...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM408505(US10358416, Compound 31 | (2S,5R)-5-(2-chloropheny...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM408506(US10358416, Compound 32 | (2S,5R)-5-(2-chlorophen...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM408507(US10358416, Compound 33 | (2S,5R)-5-(2-chloropheny...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403809((2S,5R)-5-(2-chlorophenyl)-1-(1-(4-methoxyphenyl)-...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403810((2S,5R)-5-(2-chlorophenyl)-1-(4-isopropoxybenzoyl)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403811((2S,5R)-5-(2-chlorophenyl)-1-(3-((3,5-dimethylisox...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403812((2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-5-(trifluor...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403813((2S,5R)-1-(3-(benzyloxy)benzoyl)-5-(2-chlorophenyl...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403814((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyr...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403815((2S,5R)-5-(2-chlorophenyl)-1-(2-phenylpyrimidine-5...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403816((2S,5R)-5-(2-chlorophenyl)-1-(4-(trifluoromethoxy)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403817((2S,5R)-5-(2-chlorophenyl)-1-(4-(5-cyclopropyl-1,2...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403818(4-((2S,5R)-2-carboxy-5-(2-chlorophenyl)pyrrolidine...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403819((2S,5R)-5-(2-chlorophenyl)-1-(4-phenylbutanoyl)pyr...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403820((2S,5R)-1-([1,1'-biphenyl]-4-carbonyl)-5-(3-chloro...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetFree fatty acid receptor 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM403822((2S,5R)-5-(2-chlorophenyl)-1-(3-hydroxy-5-(trifluo...)
Affinity DataEC50: >1.00E+3nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 1730 total ) | Next | Last >>
Jump to: